167 related articles for article (PubMed ID: 37679527)
1. Integrative single-cell transcriptome analysis reveals immune suppressive landscape in the anaplastic thyroid cancer.
Feng C; Tao Y; Yu C; Wang L; Liu X; Cao Y
Cancer Gene Ther; 2023 Dec; 30(12):1598-1609. PubMed ID: 37679527
[TBL] [Abstract][Full Text] [Related]
2. IL2RA
Pan Z; Bao L; Lu X; Hu X; Li L; Chen J; Jin T; Zhang Y; Tan Z; Huang P; Ge M
Biochim Biophys Acta Mol Basis Dis; 2023 Jan; 1869(1):166591. PubMed ID: 36328145
[TBL] [Abstract][Full Text] [Related]
3. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer.
Luo Y; Yang YC; Ma B; Xu WB; Liao T; Wang Y
Endocrine; 2022 Dec; 78(3):517-530. PubMed ID: 36070052
[TBL] [Abstract][Full Text] [Related]
5. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract][Full Text] [Related]
6. Early evolutionary divergence between papillary and anaplastic thyroid cancers.
Capdevila J; Mayor R; Mancuso FM; Iglesias C; Caratù G; Matos I; Zafón C; Hernando J; Petit A; Nuciforo P; Cameselle-Teijeiro JM; Álvarez C; Recio JA; Tabernero J; Matias-Guiu X; Vivancos A; Seoane J
Ann Oncol; 2018 Jun; 29(6):1454-1460. PubMed ID: 29648575
[TBL] [Abstract][Full Text] [Related]
7. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
8. Three-dimensional genome landscape comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type.
Zhang L; Xu M; Zhang W; Zhu C; Cui Z; Fu H; Ma Y; Huang S; Cui J; Liang S; Huang L; Wang H
Cell Mol Biol Lett; 2023 Jan; 28(1):1. PubMed ID: 36609218
[TBL] [Abstract][Full Text] [Related]
9. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract][Full Text] [Related]
10. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
11. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
Passaro C; Borriello F; Vastolo V; Di Somma S; Scamardella E; Gigantino V; Franco R; Marone G; Portella G
Oncotarget; 2016 Jan; 7(2):1500-15. PubMed ID: 26625205
[TBL] [Abstract][Full Text] [Related]
12. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment.
Pan Z; Xu T; Bao L; Hu X; Jin T; Chen J; Chen J; Qian Y; Lu X; Li L; Zheng G; Zhang Y; Zou X; Song F; Zheng C; Jiang L; Wang J; Tan Z; Huang P; Ge M
Mol Cancer; 2022 Oct; 21(1):190. PubMed ID: 36192735
[TBL] [Abstract][Full Text] [Related]
13. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
[TBL] [Abstract][Full Text] [Related]
14. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.
Giannini R; Moretti S; Ugolini C; Macerola E; Menicali E; Nucci N; Morelli S; Colella R; Mandarano M; Sidoni A; Panfili M; Basolo F; Puxeddu E
J Clin Endocrinol Metab; 2019 Aug; 104(8):3557-3575. PubMed ID: 30882858
[TBL] [Abstract][Full Text] [Related]
15. METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer.
Ning J; Hou X; Hao J; Zhang W; Shi Y; Huang Y; Ruan X; Zheng X; Gao M
Cell Death Differ; 2023 Oct; 30(10):2265-2279. PubMed ID: 37648786
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
[TBL] [Abstract][Full Text] [Related]
18. The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.
Pan Z; Li L; Qian Y; Ge X; Hu X; Zhang Y; Ge M; Huang P
Cancer Biol Ther; 2020 Sep; 21(9):853-862. PubMed ID: 32887540
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
20. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
